ABOUT THE CENTER FOR CLINICAL RESEARCH
If you are considering taking part in a clinical trial at The Texas Heart Institute, we encourage you to contact us. All trials must protect patient safety first and foremost. Our investigators carefully follow protocols designed to maximize benefits and reduce risks. We provide eligible patients with an informed consent process where the patients can ask questions and receive study information before deciding to participate. You might be a good fit for one of our current trials if you have any of the following conditions:
Acute or Chronic coronary syndrome
Atherosclerotic cardiovascular disease (ASCVD) “blocked arteries”
Endovascular abdominal aortic aneurysm repair (EVAR)
Recent heart attack
Transcatheter aortic valve repair (TAVR)
DCM II TRIAL (NCT04476901)
The North American Registry for Fibromuscular Dysplasia is a global research effort designed to collect clinical data and provide resources for Fibromuscular dysplasia (FMD) patients and healthcare providers. Registries collect information that can be used to study and learn more about a specific condition. This information will help improve the treatment of patients with FMD in the future.
Contact Us to Learn More at firstname.lastname@example.org
The Houston HeartReach Registry is a community-wide registry research study that aims to make improvements in heart disease prevention, diagnosis, and treatment for all women to help identify trends in heart-health risks in a diverse population of women, develop future clinical trials, and recruit women for future research studies.
This study will be a placebo-controlled, double-blind, randomized, phase 3 study to evaluate the effect of 10mg Obicetrapib in participants with Atherosclerotic Cardiovascular Disease (ASCVD) who are not adequately controlled despite maximally tolerated lipid-lowering therapy to reduce the risk of cardiovascular death, myocardial infarction, stroke and non-elective coronary revascularization.
The PROTECT IV Trial (NCT04763200)
Multi-center, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of self-administered subcutaneous selatogrel for prevention of all-cause death and treatment of acute myocardial infarction in subjects with a recent history of acute myocardial infarction.
Stem Cell Therapy vs Standard of Care in Cardiomyopathy (NCT02962661)
ALIVE Trial (NCT02931240)
Clinical Study of the BioVentrix Revivent System for Treatment of Left Ventricular Aneurysms (ALIVE)
A clinical investigation to demonstrate the safety and effectiveness of ventricular ablation therapy using the FlexAbility Sensor Enabled Ablation Catheter in patients with drug-refractory monomorphic ventricular tachycardia in whom ventricular tachycardia recurs despite antiarrhythmic drug therapy or when antiarrhythmic drugs are not tolerated or desired.
PerQseal® IDE Clinical Study – PATCH (NCT05653336)
A multicentre, single-arm, pivotal study to evaluate the safety and efficacy of the Vivasure PerQseal® Closure Device System when used to achieve haemostasis of common femoral arteriotomies created by 12 to 22 f sheaths in patients undergoing percutaneous catheter-based interventional procedures.
PORTICO IDE (NCT02000115)
The PORTICO clinical trial is a prospective, multi-center, randomized, controlled clinical study, designed to evaluate the safety and effectiveness of the Portico Transcatheter Heart Valve and Delivery Systems via transfemoral and alternative delivery methods.
Relieve HF (NCT03499236)
Reducing Lung congestion symptoms using the V-wave shunt in Advanced Heart Failure.
A randomized, controlled, multicenter, open-label trial that will study the effectiveness of implementation of a systematic LDL-C management pathway including treatment with inclisiran in participants who have experienced a recent acute coronary syndrome (ACS) and have an increased LDL-cholesterol (≥70 mg/dL) despite being treated with a statin drug.